Skip to main content
. 2020 Apr 16;15:150. doi: 10.1186/s13018-020-01648-z

Table 4.

Bone metabolism indices (x¯±s)

Item Experimental group (n = 66) Control group (n = 40) t P
BGP (ng/mL)
 Before treatment 3.39 ± 0.58 3.42 ± 0.61 0.253 0.801
 After treatment 5.78 ± 1.26ab 4.13 ± 0.94a 7.157 0.000
OPG (pg/mL)
 Before treatment 118.42 ± 12.37 120.51 ± 12.64 0.836 0.405
 After treatment 232.85 ± 24.19ab 163.79 ± 17.38a 15.747 0.000
CTX-II
 Before treatment 2.36 ± 0.27 2.41 ± 0.29 0.899 0.371
 After treatment 0.94 ± 0.08ab 1.62 ± 0.18a 18.569 0.000
COMP
 Before treatment 4.85 ± 0.62 4.90 ± 0.67 0.390 0.697
 After treatment 2.59 ± 0.31ab 3.46 ± 0.48a 11.345 0.000
RANKL
 Before treatment 84.73 ± 9.69 83.82 ± 9.44 0.473 0.637
 After treatment 54.38 ± 5.77ab 72.95 ± 7.51a 14.307 0.000

Compared with before treatment, aP < 0.05; compared with control group, bP < 0.05. BGP bone gamma-carboxy glutamic acid-containing protein, COMP cartilage oligomeric matrix protein, CTX-II crosslinked c-telopeptide of type II collagen, OPG orthopantomography, RANKL cell nuclear factor κB acceptor activating factor ligand